{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:32:30Z","timestamp":1772134350907,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T00:00:00Z","timestamp":1484524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T00:00:00Z","timestamp":1484524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1038\/bmt.2016.348","type":"journal-article","created":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T10:27:04Z","timestamp":1484562424000},"page":"683-688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma"],"prefix":"10.1038","volume":"52","author":[{"given":"L","family":"Castagna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Sarina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Crocchiolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Furst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"El-Cheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Granata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Faucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Harbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Puvinathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P J","family":"Weiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Chabannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Mokart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,16]]},"reference":[{"key":"BFbmt2016348_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.bmt.1705977","volume":"41","author":"KJ Thomson","year":"2008","unstructured":"Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008; 41: 765\u2013770.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016348_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.bbmt.2008.12.506","volume":"15","author":"L Castagna","year":"2009","unstructured":"Castagna L, Sarina B, Todisco E, Magagnoli M, Balzarotti M, Bramanti S et al. Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma. Biol Blood Marrow Transplant 2009; 15: 432\u2013438.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016348_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3324\/haematol.13441","volume":"94","author":"SP Robinson","year":"2009","unstructured":"Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94: 230\u2013238.","journal-title":"Haematologica"},{"key":"BFbmt2016348_CR4","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","volume":"115","author":"B Sarina","year":"2010","unstructured":"Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010; 115: 3671\u20133677.","journal-title":"Blood"},{"key":"BFbmt2016348_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"A Sureda","year":"2012","unstructured":"Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study- a prospective clinical trial by the Grupo Espa\u00f1ol de Linfomas\/Trasplante de M\u00e9dula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012; 97: 310\u2013317.","journal-title":"Haematologica"},{"key":"BFbmt2016348_CR6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3109\/10428194.2013.802780","volume":"55","author":"M Messer","year":"2014","unstructured":"Messer M, Steinzen A, Verv\u00f6lgyi E, Lerch C, Richter B, Dreger P et al. Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review. Leuk Lymphoma 2014; 55: 296\u2013306.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2016348_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641\u2013650.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016348_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","volume":"14","author":"LM Burroughs","year":"2008","unstructured":"Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1279\u20131287.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016348_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/bmt.2013.166","volume":"49","author":"A Raiola","year":"2014","unstructured":"Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F, Bramanti S et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant 2014; 49: 190\u2013194.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016348_CR10","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912\u20132919.","journal-title":"Blood"},{"key":"BFbmt2016348_CR11","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.bbmt.2014.02.001","volume":"20","author":"L Castagna","year":"2014","unstructured":"Castagna L, Crocchiolo R, Furst S, Bramanti S, El Cheikh J, Sarina B et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014; 20: 724\u2013729.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016348_CR12","first-page":"825","volume":"15","author":"D Przepiorka","year":"1994","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016348_CR13","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016348_CR14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695\u2013706.","journal-title":"Stat Med"},{"key":"BFbmt2016348_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFbmt2016348_CR16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"D Cox","year":"1972","unstructured":"Cox D . Regression models and life tables. J R Stat Soc (B) 1972; 34: 187\u2013220.","journal-title":"J R Stat Soc (B)"},{"key":"BFbmt2016348_CR17","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","volume":"127","author":"AS Kanate","year":"2016","unstructured":"Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood 2016; 127: 938\u2013947.","journal-title":"Blood"},{"key":"BFbmt2016348_CR18","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","volume":"34","author":"N Ghosh","year":"2016","unstructured":"Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol 2016; 34: 3141\u20133149 pii: JCO663476.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016348_CR19","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183\u20132189.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016348_CR20","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","volume":"125","author":"AK Gopal","year":"2015","unstructured":"Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015; 125: 1236\u20131243.","journal-title":"Blood"},{"key":"BFbmt2016348_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311\u2013319.","journal-title":"N Engl J Med"},{"key":"BFbmt2016348_CR22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.V124.21.290.290","volume":"124","author":"CH Moskowitz","year":"2014","unstructured":"Moskowitz CH, Ribrag V, Michot JM . PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). Blood 2014; 124: 290.","journal-title":"Blood"},{"key":"BFbmt2016348_CR23","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","volume":"23","author":"Stem Cell Trialists","year":"2005","unstructured":"Stem Cell Trialists . Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074\u20135087.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016348_CR24","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","volume":"31","author":"A Bashey","year":"2013","unstructured":"Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013; 31: 1310\u20131316.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016348_CR25","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","volume":"125","author":"SR McCurdy","year":"2015","unstructured":"McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bola\u00f1os-Meade J, Rosner GL et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015; 125: 3024\u20133031.","journal-title":"Blood"},{"key":"BFbmt2016348_CR26","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","volume":"100","author":"SP Robinson","year":"2002","unstructured":"Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310\u20134316.","journal-title":"Blood"},{"key":"BFbmt2016348_CR27","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/S0140-6736(05)66659-7","volume":"365","author":"KS Peggs","year":"2005","unstructured":"Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 1934\u20131941.","journal-title":"Lancet"},{"key":"BFbmt2016348_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bbmt.2005.09.009","volume":"12","author":"I Alvarez","year":"2006","unstructured":"Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12: 172\u2013183.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016348_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1600-0609.2007.00814.x","volume":"78","author":"E Todisco","year":"2007","unstructured":"Todisco E, Castagna L, Sarina B, Mazza R, Anastasia A, Balzarotti M et al. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. Eur J Haematol 2007; 78: 322\u2013329.","journal-title":"Eur J Haematol"},{"key":"BFbmt2016348_CR30","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","volume":"21","author":"P Corradini","year":"2007","unstructured":"Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316\u20132323.","journal-title":"Leukemia"},{"key":"BFbmt2016348_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3324\/haematol.11828","volume":"93","author":"P Anderlini","year":"2008","unstructured":"Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93: 257\u2013264.","journal-title":"Haematologica"},{"key":"BFbmt2016348_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bbmt.2008.11.011","volume":"15","author":"MP Devetten","year":"2009","unstructured":"Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009; 15: 109\u2013117.","journal-title":"Biol Blood Marrow Transplant"}],"updated-by":[{"DOI":"10.1038\/bmt.2017.26","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T00:00:00Z","timestamp":1493769600000}}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2016348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016348","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bmt.2016.348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T17:04:18Z","timestamp":1718989458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2016348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,16]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["BFbmt2016348"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.348","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.730450399.793569275","asserted-by":"object"}]},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,16]]},"assertion":[{"value":"12 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2017","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}